Spyre Therapeutics (SYRE) Payables (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Payables data on file, last reported at $56.0 million in Q1 2026.

• Quarterly Payables rose 20.33% year-over-year to $56.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.0 million (up 20.33% YoY) and the FY2025 annual result came in at $31.7 million, up 23.22% from the prior year.
• Payables advanced to $56.0 million in Q1 2026, from $31.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $63.6 million in Q2 2025 to a low of $2.0 million in Q2 2022.
• A 5-year average of $20.6 million and a median of $13.8 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables jumped 1108.58% — and 2024, when it plunged 75.19%.
• Tracing SYRE's Payables over 5 years: stood at $4.2 million in 2022, then slumped by 45.28% to $2.3 million in 2023, then surged by 1026.25% to $25.7 million in 2024, then gained by 23.22% to $31.7 million in 2025, then surged by 76.37% to $56.0 million in 2026.
• The last three Payables figures came in at $56.0 million (Q1 2026), $31.7 million (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.